Analyst Estimates, Revenue Estimates, Earnings Report, Immune Pharmaceuticals, Inc., IMNP

0
21

Immune Pharmaceuticals, Inc. (IMNP) will report its next earnings on Feb 14 BMO. The company reported the earnings of $-3.2/Share in the last quarter where the estimated EPS by analysts was $-2.7/share. The difference between the expected and actual EPS was $-0.5/share, which represents an Earnings surprise of -18.5%.

Some buy side analysts are also providing their Analysis on Immune Pharmaceuticals, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Immune Pharmaceuticals, Inc. might touch $3 high while the Average Price Target and Low price Target is $3 and $3 respectively.

The Relative Volume of the company is 7.24 and Average Volume (3 months) is 767.35 million.

The company shows its Return on Assets (ROA) value of -127.5%.

While looking at the Stock’s Performance, Immune Pharmaceuticals, Inc. currently shows a Weekly Performance of 7.31%, where Monthly Performance is -25.85%, Quarterly performance is -62.23%, 6 Months performance is -78.53% and yearly performance percentage is -84.23%. Year to Date performance value (YTD perf) value is 7.39%. The Stock currently has a Weekly Volatility of 10.52% and Monthly Volatility of 9.99%.